Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Sets New 12-Month High – Here’s What Happened

Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) reached a new 52-week high during trading on Monday. The stock traded as high as $98.49 and last traded at $98.3510, with a volume of 309,132 shares traded. The stock had previously closed at $93.86.

Analysts Set New Price Targets

KNSA has been the subject of several research analyst reports. Citigroup raised their target price on shares of Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. Wells Fargo & Company boosted their price target on shares of Kiniksa Pharmaceuticals International from $87.00 to $110.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 28th. Weiss Ratings downgraded shares of Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c-)” rating in a report on Wednesday, October 28th. JPMorgan Chase & Co. raised their price objective on Kiniksa Pharmaceuticals International from $107.00 to $122.00 and gave the company an “overweight” rating in a research report on Friday, October 30th. Finally, Canaccord Genuity Group lifted their target price on Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a “buy” rating in a report on Wednesday, July 29th. Seven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $100.57.

Kiniksa Pharmaceuticals International Stock Up 0.9%

The stock’s 50 day moving average is $81.20 and its 200-day moving average is $61.91. The company has a market cap of $7.54 billion, a PE ratio of 73.81 and a beta of 0.07.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its quarterly earnings data on Tuesday, October 27th. The company reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of $0.37 by $0.19. Kiniksa Pharmaceuticals International had a net margin of 11.58% and a return on equity of 17.27%. The business had revenue of $285.97 million during the quarter, compared to analysts’ expectations of $260.66 million. On average, analysts anticipate that Kiniksa Pharmaceuticals International, plc will post 1.30 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Sanj K. Patel sold 151,300 shares of the business’s stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $94.71, for a total transaction of $14,329,623.00. Following the transaction, the chief executive officer owned 774,500 shares of the company’s stock, valued at approximately $73,352,895. The trade was a 16.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Ross Moat sold 27,977 shares of the business’s stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $92.36, for a total value of $2,583,955.72. Following the transaction, the chief operating officer directly owned 10,294 shares in the company, valued at approximately $950,753.84. This represents a 73.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 831,022 shares of company stock worth $77,475,599. 51.98% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Focus Advisor Solutions LLC purchased a new position in Kiniksa Pharmaceuticals International during the 3rd quarter valued at $224,000. Voya Investment Management LLC increased its stake in Kiniksa Pharmaceuticals International by 5.5% in the third quarter. Voya Investment Management LLC now owns 8,522 shares of the company’s stock worth $636,000 after purchasing an additional 445 shares during the period. Global Retirement Partners LLC lifted its position in shares of Kiniksa Pharmaceuticals International by 315.5% during the third quarter. Global Retirement Partners LLC now owns 428 shares of the company’s stock worth $32,000 after purchasing an additional 325 shares during the last quarter. Virtus Advisers LLC bought a new stake in shares of Kiniksa Pharmaceuticals International during the third quarter worth $139,000. Finally, JW Asset Management LLC bought a new stake in shares of Kiniksa Pharmaceuticals International during the third quarter worth $1,641,000. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International plc is a biopharmaceutical company focused on developing and commercializing treatments for patients with autoimmune and inflammatory diseases. The company was established in 2015 and has operations in the United States and internationally. Kiniksa’s marketed medicine, Arcalyst (rilonacept), is approved in the United States to treat recurrent pericarditis and reduce the risk of recurrence in adults and certain pediatric patients. It is also approved for cryopyrin-associated periodic syndromes, a group of rare autoinflammatory conditions.